Galaxy Medicare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Galaxy Medicare Limited's achieved publicly listed status following its IPO debut on Sep 17, 2025 at the NSE platform. The offering successfully mobilized 41,32,000 Shares, with 33,08,000 Shares allocated to corporate growth initiatives and ₹4.45 Cr providing liquidity to existing shareholders.
Investment participation occurred within the established price band of ₹51 to ₹54, starting from minimum lots of 2000 shares. The subscription window from Sep 10, 2025 through Sep 12, 2025 enabled investor participation across market segments.
Share allocation was completed on Sep 15, 2025, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Galaxy Medicare Limited, incorporated in July 1992, is engaged in the manufacturing and export of medical devices, POP bandages, and surgical dressings in India. The company uses premium-grade raw materials sourced from authentic vendors to ensure quality in its production. Its product portfolio includes surgical dressings, plaster of Paris bandages, adhesive tapes, compression bandages, gauze products, wound care solutions, and orthopedic items. Galaxy Medicare operates through multiple business verticals, such as manufacturing and branding under its flagship names like POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE, GYPSONET, GYPSOCHLOR, and FIXCAN, among others. It also caters to OEM requirements by sourcing, designing, manufacturing, and testing products according to brand owners’ specifications on a Principal-to-Principal basis. Additionally, the company participates in institutional sales through government tenders on the GEM portal, exports its products internationally, and trades in surgical devices and dressings. With 27 registered trademarks in India, its products are widely accepted by the medical community and supplied across the country to government health departments, corporate hospitals, and private organizations. The company holds ISO 9001:2015 and ISO 13485:2016 certifications, reflecting its commitment to quality and adherence to global standards. As of March 2025, Galaxy Medicare employs 190 people across various departments.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Proven Industry Track Record – Over 30 years of operations with strong brand reputation and trusted customer relationships.
- Wide & Diversified Product Portfolio – 27+ registered trademarks catering to multiple medical needs, minimizing product concentration risk.
- Multiple Revenue Streams – Balanced income from branded sales, OEM partnerships, government contracts, and exports ensuring stability and growth.
- High Customer Concentration Risk – Heavy reliance on a few key customers, where the loss of any major account could severely affect revenue stability and profitability.
- Raw Material Supply & Cost Risk – Dependence on timely availability of raw materials; shortages or price escalations may disrupt operations and compress margins.
- Legal & Compliance Exposure – Pending litigations and compliance requirements pose potential risks to reputation, financial health, and business continuity.
- Mr. Dillip Kumar Das
- Mr. Subhasish Das
- Mrs. Kiran Das
Galaxy Medicare Limited
Cameo Corporate Services Limited